In multivariableanalysis, factors statistically significantly associated with receipt of second-linetherapy included longer duration of first-line therapy, lack of body weight lossduring first-line therapy, younger age, having a tumor that overexpressed HER2, andpatients with an initial diagnosis of metastatic disease (Table 4). This evidence concerns the gene ERBB2 and neoplasm.